🇺🇸 FDA
Patent

US 8980275

Targeted heterologous antigen presentation on calicivirus virus-like particles

granted A61KA61K2039/5256A61K2039/5258

Quick answer

US patent 8980275 (Targeted heterologous antigen presentation on calicivirus virus-like particles) held by Takeda Vaccines, Inc. expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Vaccines, Inc.
Grant date
Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/5256, A61K2039/5258, A61K2039/55505, A61K2039/55572